Medtronic inks deal for Viz.ai’s stroke tech
Monday, July 22, 2019
San Francisco-based Viz.ai’s LVO Stroke platform is designed to analyze computed tomography results and notify providers of potential strokes. The technology won 510(k) clearance from the FDA in February 2018. The deal with Fridley, Minn.-based Medtronic calls for it to distribute LVO Stroke, aiming to place it into every U.S. stroke center.
“Viz.ai is fast emerging as the leader in artificial intelligence in stroke care. We are excited about this partnership because Viz.ai’s technology has the potential to significantly reduce the time it takes for patients suspected of LVO stroke to receive the care they need,” neurovascular GM Stacey Pugh said in prepared remarks. “Viz.ai’s software coupled with our network is going to increase access to needed therapies. It greatly complements our existing portfolio.”
“Medtronic is an innovative company focused on therapies that extend life and restore health,” added Viz.ai co-founder & CEO Dr. Chris Mansi. “As the largest medical device company in the world, Medtronic is an ideal partner to help physicians access Viz.ai’s cutting-edge technology to ensure as many patients get the care they need as quickly as possible.”
“Viz.ai allows clinicians to receive an alert for suspected large vessel occlusions and the corresponding visual data,” Dr. Elad Levy, of the University at Buffalo’s Jacobs School of Medicine & Biomedical Sciences, said in a press release. “The combination of AI powered alerts, mobile image viewing, and HIPAA compliant communication facilitates synchronization of stroke care with great potential to impactfully reduce door-to-needle time and help an increased number of patients.”